DLL4 antibody and application thereof

A DLL4 antibody with a defined scFv sequence, constructed via phage display, effectively binds to human and mouse DLL4 proteins, facilitating anti-tumor therapies by integrating into IgG antibodies and other structures for targeted tumor detection and treatment.

CN119060183APending Publication Date: 2024-12-03SHENZHEN FIRST CONDOR BIOSCIENCE CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411254297.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-09
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

Existing technologies lack effective antibodies that can specifically bind to human and mouse DLL4 proteins, hindering the development of therapeutic strategies and drugs targeting DLL4 targets for tumor cell killing.

Method used

A DLL4 antibody with a specific scFv sequence, comprising particular amino acid sequences for its heavy and light chain variable regions, is constructed using phage display technology, enabling it to bind to both human and mouse DLL4 proteins, and can be incorporated into IgG antibodies, bispecific T cell engagers (BiTEs), and Chimeric Antigen Receptors (CARs).

Benefits of technology

The DLL4 antibody demonstrates high affinity and specificity for DLL4, allowing for effective in vivo and in vitro anti-tumor effects, and can be used to develop human biological drugs without immunogenicity, providing a platform for detecting and treating various solid tumors.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119060183A_ABST
    Figure CN119060183A_ABST
Patent Text Reader

Abstract

The invention discloses a DLL4 antibody, an scFv sequence of the DLL4 antibody contains a 4P14 sequence, and 4P14 scFv can be transformed into Bi TE, CAR and other structures and has an in-vivo and in-vitro anti-tumor effect; the 4P14 of the scFv is a humanized antibody, has no immunogenicity to a human body, and can be directly used for developing a biological medicine for human without being subjected to humanized transformation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the field of antibody biology, and in particular to a DLL4 antibody and application thereof. Background Art

[0002] Phage display technology is a technology used to screen and identify proteins, peptides, antibodies and other biological molecules. This technology uses bacteriophages as carriers to insert the genes of target molecules into the phage genome so that these molecules can be displayed on the surface of the phage. This display method has a wide range of applications in biology and biotechnology. Phage display is often used to screen antibodies or antibody fragments to develop high-affinity antibodies against specific antigens.

[0003] The fully human antibody library constructed using phage display technology can be used to screen and develop human antibodies. It contains a large number of different antibody gene sequences, allowing researchers to screen and generate fully human antibodies with specific binding abilities and properties. This fully human antibody has important applications in biomedical research, therapeutic antibody development, drug discovery and other fields.

[0004] DLL4 (Delta-like ligand 4) is one of the key ligands in the Notch signaling pathway. The Notch signaling pathway plays an important role in biological processes such as cell differentiation, proliferation, apoptosis and intercellular communication, and plays a key role in embryonic development, tissue repair, immune response, angiogenesis, etc. DLL4 plays multiple roles in Notch signaling, participates in the occurrence of cancer and vascular diseases, and is a potential biological therapeutic target. Therefore, it is necessary to construct DLL4 antibodies by screening fully human antibodies against DLL3, and develop therapeutic strategies and drugs targeting DLL4 targets. Summary of the invention

[0005] Based on the above problems, the problem to be solved by the present invention is to provide an antibody that can specifically bind to human and mouse DLL4 proteins and its application; by constructing DLL4 antibodies, therapeutic strategies and drugs targeting DLL4 targets are developed to achieve in vivo killing of tumor cells.

[0006] The technical solution of the present invention is as follows:

[0007] A DLL4 antibody, wherein the scFv sequence of the DLL4 antibody contains a 4P14 sequence; wherein the amino acid sequence of the heavy chain variable region (VH) of the scFv sequence is as shown in SEQ ID NO:11, and the amino acid sequence of the light chain variable region (VL) of the scFv sequence is as shown in SEQ ID NO:12.

[0008] In one embodiment, in the above-mentioned DLL4 antibody, the amino acid sequences of the three heavy chain complementary determining regions HCDR1, HCDR2, and HCDR3 in the 4P14 sequence and the amino acid sequences of the three light chain complementary determining regions LCDR1, LCDR2, and LCDR3 in the 4P14 sequence are as follows: when the 4P14 sequence is a chothia structure, in the 4P14 sequence: the amino acid sequence of HCDR1 is GFTLSDY, the amino acid sequence of HCDR2 is SSSGST, the amino acid sequence of HCDR3 is AGSAGAAGSYYYYGMDV, the amino acid sequence of LCDR1 is QASQDISNYLN, the amino acid sequence of LCDR2 is DASNLET, and the amino acid sequence of LCDR3 is QQSHSSQYT; or

[0009] When the 4P14 sequence is a Kabat structure, in the 4P14 sequence: the amino acid sequence of HCDR1 is DYYMS, the amino acid sequence of HCDR2 is YISSSGSTIYYADSVKG, the amino acid sequence of HCDR3 is AGSAGAAGSYYYYGMDV, the amino acid sequence of LCDR1 is QASQDISNYLN, the amino acid sequence of LCDR2 is DASNLET, and the amino acid sequence of LCDR1 is QQSHSSQYT.

[0010] The above-mentioned DLL4 antibody can be used to prepare IgG antibodies, bispecific T cell engagers (BiTEs) and / or CARs, and the VH and VL sequences of DLL4 are included in the structures of IgG antibodies, BiTEs or CARs; in this way, the VH and VL sequences of DLL1 become part of the structures of IgG antibodies, BiTEs or CARs; among them, IgG antibodies include antibodies such as IgG1, IgG2, IgG3 and IgG4.

[0011] Any of the above-mentioned DLL4 antibodies, IgG antibodies, bispecific T cell engagers (BiTE) and CARs can be used to prepare detection reagents for detecting tumor cells, cancer cells and other drugs, as well as to prepare biological preparations for treating tumors, cancers and other drugs.

[0012] The DLL4 antibody provided by the present invention includes the scFv antibody 4P14 that can simultaneously bind to DLL4 from human and mouse sources, and the 4P14 scFv can be transformed into structures such as BiTE and CAR, so that it has in vivo and in vitro anti-tumor effects; at the same time, the scFv 4P14 is a humanized antibody, which is non-immunogenic to the human body and can be directly used to develop human biological drugs without the need for humanization transformation. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] Figure 1This is the affinity curve of 4P14-IgG1 to human and mouse DLL4 detected by ELSIA in Example 3;

[0014] Figure 2 This is a specific diagram of 4P14 detected by flow cytometry in 293T-DLL4 cells, 293T-DLL1 cells and 293T-DLL3 cells in Example 4;

[0015] Figure 3 This is a schematic diagram of the structure of CD3×DLL4 BiTE in Example 5;

[0016] Figure 4 This is a photo of the CD3×DLL4 BiTE protein in Example 5;

[0017] Figure 5 It is a flow cytometry graph of CD3×DLL4 BiTE binding to 293T-DLL4 and T cells in Example 6;

[0018] Figure 6 This is a fluorescence curve diagram of the ability of CD3×DLL4 BiTE to activate T cells detected by the luciferase reporter gene method in Example 6;

[0019] Figure 7 It is a killing rate curve diagram of CD3×DLL4 BiTE-mediated T cell killing of target cell 293T-DLL4 in Example 6;

[0020] Figure 8 This is a schematic diagram of the 4P14 CAR structure in Example 7;

[0021] Fig. 9 This is a graph showing the 4P14 CAR positivity rate of T cells detected by flow cytometry in Example 7;

[0022] Fig.10 This is a graph showing the killing rate of 4P14 CAR-T cells against target cells 293T-DLL4 in Example 8;

[0023] Fig.11 This is a curve diagram of the change in mouse tumor volume in Example 9;

[0024] Fig.12 The figure is a curve diagram of the mouse survival rate in Example 9; DETAILED DESCRIPTION

[0025] The preferred embodiments of the present invention are further described in detail below in conjunction with the accompanying drawings.

[0026] The DLL4 antibody provided by the present invention, its construction, screening scheme, and preparation of DLL4-IgG antibody, etc., and its related process steps are as follows.

[0027] 1. Construction and screening of human scFv phage display library

[0028] 1. Construction of scFv phage display library

[0029] The specific process steps are as follows:

[0030] S11, mixed human PBMCs were obtained, mRNA was extracted using Trizol and chloroform, and the mRNA was reverse transcribed into cDNA using SuperScriptTM IVFirt-Strand cDNA Synthesis Reaction Kit (commercially purchased from Thermo Fisher Scientific);

[0031] S12. Using cDNA as a template, specific primers were used to amplify the nucleotide sequences of the light chain VL and heavy chain VH of the human DLL4 antibody, respectively, and the process was as follows:

[0032] S121, VL and VH were amplified by overlapping PCR to form a scFv gene fragment VH-(G4S)3-VL connected with a (G4S)3 linker, and NcoI (purchased from Bao Ri Yi Biotechnology (Beijing) Co., Ltd.) and NheI (purchased from Bao Ri Yi Biotechnology (Beijing) Co., Ltd.) restriction sites were introduced at both ends;

[0033] S122, the scFv gene fragment was double-digested with NcoI and NheI, and ligated to the pHEN1 vector (purchased from Wuhan Huaerna Biotechnology Co., Ltd.) using T4 ligase (purchased from Baoriyi Biotechnology (Beijing) Co., Ltd.) to construct a pHEN1-scFv vector;

[0034] S123, transforming TG1 competent cells with pHEN1-scFv to prepare a scFv library;

[0035] S124. Use helper phage M13KO7 (commercially purchased from Chengdu Gugel Biotechnology Co., Ltd.) to infect the scFv library and package the library into a scFv phage display library.

[0036] 2. Screening of scFv phage display library

[0037] Using recombinant human and mouse DLL4 as antigens, DLL4 was coated on an ELISA plate and a human scFv phage display library was selected using a solid phase screening method. The specific process steps are as follows:

[0038] S21, recombinant human and mouse DLL4 proteins were coated in each well of a Corning EIA / RIA 96-well plate and incubated at 4°C for 12 h, after which each well was blocked alternately with PBS (pH 7.4) containing 3% skim milk and 5% BSA in different screening rounds;

[0039] S22, after incubation for 12 hours, add the human scFv phage display library obtained in step S12 of this embodiment to each well and incubate for 1 hour; then wash the well plate with PBST;

[0040] S23. Elute the scFv phage display library with triethylamine eluent at a volume of 100 μL / well; collect the washing solution after washing, add an equal volume of Tris-HCl, mix well, and obtain the eluted scFv phage display library.

[0041] 3. Amplification and collection of scFv phage display library

[0042] S31, after infecting TG1 bacteria in the logarithmic growth phase with the eluted scFv phage display library obtained in step S23, add M13KO7, place at 37°C for 30 minutes, and then culture on a shaker at 37°C and 180 rpm for 1 hour; then transfer to a centrifuge tube, centrifuge at 5000 rpm for 10 minutes at room temperature, remove the supernatant, and collect the bacterial precipitate; resuspend the bacterial precipitate with a culture medium containing ampicillin and kanamycin, and culture the resuspension on a shaker at 30°C and 220 rpm for 12 hours to obtain a culture;

[0043] S32, transfer the culture into a 50mL centrifuge tube, centrifuge at 4°C and 12000rpm for 10min; collect the supernatant and add a PEG / NaCl mixture, and the volume ratio of the supernatant to the mixture is 1:4; place the centrifuge tube in an ice bath for 4h; then transfer to another centrifuge tube, centrifuge at 4°C and 12000rpm for 20min, discard the supernatant, collect the precipitate and resuspend it with 1mL PBS, centrifuge the resuspended solution at 4°C and 12000rpm for 10min, collect the supernatant and transfer it to a new 1.5mL centrifuge tube, screen and obtain the scFv phage display library; extract the display library samples for titer determination;

[0044] S33, titer determination:

[0045] S331. Day 1. Dilute 10 μL of the scFv phage display library obtained in step S32 to 10 μL with culture medium in a 10-fold gradient. -4 ;

[0046] S332, taking each gradient dilution of the scFv phage display library and inoculating it into 200 μl of freshly cultured TG1 bacterial solution with OD600=0.4-0.5, and incubating at 37° C. for 30 min to obtain a scFv phage display library slurry;

[0047] S333, spreading the slurry on a plate containing ampicillin resistance to obtain colonies;

[0048] S334. On the second day, the colonies on the plate were counted and the titer of the scFv phage display library was calculated; the calculation formula was as follows:

[0049] scFv phage display library titer = number of phage monoclones × dilution (pfu / 10uL).

[0050] 4. ELISA verification and sequencing of phage monoclones

[0051] S41, according to the titer determination result in step S33, determine whether to screen the amount of the scFv phage display library again, and whether to repeat the above steps 1 to 3 for 3 to 5 times until the desired amplified scFv phage display library is obtained;

[0052] S42, after the screening is completed, the amplified scFv phage display library is coated on a plate containing ampicillin resistance, and a phage single clone is taken for ELISA detection to verify the binding activity;

[0053] S43. In step S42, select the phage monoclones with the highest binding activity (preferably 5) for sequencing, and select the different sequences in the sequencing results as candidate DLL4 antibody sequences, such as the 4P14 sequence in the DLL4 antibody sequence.

[0054] The sequencing results were translated into the protein amino acid sequence as follows:

[0055] The amino acid sequence of 4P14-scFv is shown in SEQ ID NO: 10:

[0056] QVQLVQSGGGLVKPGGSLRLSCAASGFTLSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARAGSAGAAGSYYYYGMDVWGQGTTVTV SSGGGGSGGGGSGGGGSDIQLTQSPSSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGRDFSLTISSLQPEDFATYYCQQSHSSQYTFGQGTKVEIK;

[0057] in,

[0058] 1.1) The amino acid sequence of the heavy chain variable region (VH) of the scFv sequence is shown in SEQ ID NO: 11:

[0059] QVQLVQSGGGLVKPGGSLRLSCAASGFTLSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARAGSAGAAGSYYYYGMDVWGQGTTVTVSS;

[0060] 1.2) The amino acid sequence of the light chain variable region (VL) of the scFv sequence is shown in SEQ ID NO: 12:

[0061] DIQLTQSPSSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGRDFSLTISSLQPEDFATYYCQQSHSSQYTFGQGTKVEIK;

[0062] Accordingly, the amino acid sequences of the three heavy chain complementary determining regions (HCDR1, HCDR2, HCDR3) and the three light chain complementary determining regions (LCDR1, LCDR2, LCDR3) contained in the 4P14 sequence are as follows; wherein:

[0063] If 4P14 is chothia, then:

[0064] The amino acid sequence of HCDR1 is GFTLSDY;

[0065] The amino acid sequence of HCDR2 is SSSGST;

[0066] The amino acid sequence of HCDR3 is AGSAGAAGSYYYYGMDV;

[0067] The amino acid sequence of LCDR1 is QASQDISNYLN;

[0068] The amino acid sequence of LCDR2 is DASNLET;

[0069] The amino acid sequence of LCDR3 is QQSHSSQYT;

[0070] or

[0071] If 3P53 is Kabat, then:

[0072] The amino acid sequence of HCDR1 is DYYMS;

[0073] The amino acid sequence of HCDR2 is YISSSGSTIYYADSVKG;

[0074] The amino acid sequence of HCDR3 is AGSAGAAGSYYYYGMDV;

[0075] The amino acid sequence of LCDR1 is QASQDISNYLN;

[0076] The amino acid sequence of LCDR2 is DASNLET;

[0077] The amino acid sequence of LCDR1 is QQSHSSQYT.

[0078] 2. Preparation of DLL4-IgG Antibody

[0079] First, take the DLL4 antibody heavy chain VH and light chain VL sequences in the first item above;

[0080] Secondly, the VH region of the IgG antibody was replaced with the VH sequence of the DLL4 antibody; the VL region of the kappa light chain of the IgG antibody was replaced with the VL sequence of the DLL4 antibody;

[0081] Next, the replaced kappa light chain VL and heavy chain VH were constructed into the expression vector pcDNA3.1 to obtain DLL4-IgG antibody;

[0082] Finally, HEK293 cells were transiently transfected and DLL4-IgG antibodies were purified using a Protein A column.

[0083] The scFv sequence in the DLL4 antibody, and its 4P14-IgG constructed from the VH and VL sequences derived from the 4P14 sequence, have a high affinity to human and mouse DLL4 sequences, can recognize human and mouse DLL4 protein molecules, DLL4 expressed on the cell membrane, and DLL4 expressed on tissues, and can be used in ELISA, WB, IHC and other detection methods, making DLL4 have good application prospects in detecting molecular, cellular and tissue levels.

[0084] Therefore, the above-mentioned DLL4, DLL4-IgG antibody, bispecific T cell engager (BiTE), CAR and other structures can be used to prepare detection reagents for detecting solid tumors such as tumors or cancers, or to prepare drugs for treating tumors, cancers, etc.

[0085] The tumor or cancer of the present invention is a type of solid tumor, which mainly includes brain glioma, germ cell tumor, sarcoma, biliary tract cancer, bladder cancer, bone cancer, brain and CNS cancer, breast cancer, peritoneal cancer, cervical cancer, choriocarcinoma, colon and rectal cancer, connective tissue cancer, digestive system cancer, endometrial cancer, esophageal cancer, eye cancer, head and neck cancer, gastric cancer, glioblastoma (GBM), liver cancer, hepatoma, intraepithelial neoplasia, kidney cancer, laryngeal cancer, liver tumor, lung cancer, lymphoma, melanoma, myeloma, neuroblastoma, oral cancer, ovarian cancer, pancreatic cancer, prostate cancer, retinoblastoma, rhabdomyosarcoma, rectal cancer, respiratory system cancer, salivary gland cancer, skin cancer, squamous cell carcinoma, gastric cancer, testicular cancer, thyroid cancer, uterine or endometrial cancer, malignant tumors of the urinary system and other cancers and sarcomas.

[0086] The present invention is further described in detail below through some embodiments.

[0087] Example 1 Phage Screening of DLL4 Antibodies

[0088] 1.1 Construction of human scFv phage display library

[0089] Mixed human PBMCs were obtained, and mRNA was extracted using Trizol and chloroform. The mRNA was reverse transcribed into cDNA using SuperScriptTM IV Firt-Strand cDNA Synthesis Reaction Kit (commercially purchased from Thermo Fisher Scientific).

[0090] Using cDNA as a template, specific primers were used to amplify the light chain VL and heavy chain VH sequences of human DLL4 antibody respectively; the process is as follows:

[0091] VL and VH were amplified by overlapping PCR into scFv gene fragments connected by (G4S)3 linkers, and NcoI and NheI restriction sites were introduced at both ends;

[0092] The scFv gene fragment was double-digested with NcoI and NheI and ligated into the pHEN1 vector using T4 ligase to construct the pHEN1-scFv vector;

[0093] Transform TG1 competent cells with pHEN1-scFv to prepare a scFv library;

[0094] The scFv library was infected with helper phage M13KO7 and packaged into a human scFv phage display library.

[0095] 1.2 Screening of scFv phage display library

[0096] Recombinant human and mouse DLL4 proteins were coated in each well of a Corning EIA / RIA 96-well plate and incubated at 4°C for 12 h. Each well was blocked alternately with 300 μL of blocking solution containing 3% skim milk in PBS (pH 7.4) and 5% BSA.

[0097] After incubation for 12 h, the blocking solution was discarded, and the human scFv phage display library obtained in step 1.1 of this example was added to each well; the phage display library was diluted to 1% with the blocking solution, 100 μL was added to each well, and incubated at 37° C. for 1 h; then the plate was washed with PBS containing 0.05% Tween-20 (PBST).

[0098] The scFv phage display library was eluted with triethylamine elution solution at a volume of 100 μL / well; after washing, the washing solution was collected, and Tris-HCl with an equal volume to the washing solution was added and mixed evenly to obtain the eluted scFv phage display library; the titer of the eluted scFv phage display library was measured.

[0099] 1.3 Amplification and collection of scFv phage display library

[0100] After infecting TG1 bacteria in the logarithmic growth phase with the scFv phage display library eluted in step 1.2 of this example, M13KO7 was added, and the mixture was placed at 37°C for 30 minutes, and then cultured on a shaker at 37°C and 180 rpm for 1 hour; then the mixture was transferred to a centrifuge tube, centrifuged at 5000 rpm at room temperature for 10 minutes, the supernatant was removed, and the bacterial precipitate was collected; the bacterial precipitate was resuspended in a culture medium containing ampicillin and kanamycin, and the resuspension was cultured on a shaker at 30°C and 220 rpm for 12 hours to obtain a culture.

[0101] The culture was transferred to a 50 mL centrifuge tube and centrifuged at 4°C and 12,000 rpm; the supernatant was collected and added to a PEG / NaCl mixture, and the volume ratio of the supernatant to the mixture was 1:4; the centrifuge tube was placed in an ice bath for 4 hours; then transferred to another centrifuge tube, centrifuged at 4°C and 12,000 rpm for 20 minutes, the supernatant was discarded, the precipitate was collected and resuspended with 1 mL PBS, the resuspended solution was centrifuged at 4°C and 12,000 rpm for 10 minutes, the supernatant was collected and transferred to a new 1.5 mL centrifuge tube, and the scFv phage display library was screened; samples of the phage display library were extracted for titer determination.

[0102] 1.4 Titer determination

[0103] On the first day, 10 μL of the eluted scFv phage display library was diluted 10-fold in the culture medium to 10 -4 ;

[0104] Each gradient dilution of the scFv phage display library was inoculated into 200 μl of freshly cultured TG1 bacterial solution with an OD600 of 0.4 to 0.5, and incubated at 37°C for 30 min to obtain a scFv phage display library slurry;

[0105] Spread the slurry on a plate containing ampicillin resistance to obtain colonies;

[0106] On the second day, the colonies on the plate were counted and the titer of the eluted scFv phage display library was calculated; the calculation formula is as follows:

[0107] scFv phage display library titer = number of phage clones × dilution (pfu / 10uL).

[0108] 1.5 ELISA verification and sequencing of phage monoclones

[0109] According to the titer determination result in step 1.4 of this example, it is determined whether to screen the amount of the scFv phage display library again, and whether to repeat the steps in items 1.1 to 1.3 for 3 to 5 times until the amplified scFv phage display library is obtained.

[0110] After the screening is completed, the amplified scFv phage display library is spread on a plate containing ampicillin resistance, and the phage single clone is taken for ELISA detection to verify the binding activity;

[0111] The phage monoclones with the highest binding activity (preferably 5) were selected for sequencing, and the different sequences in the sequencing results were selected as the scFv sequences in the candidate DLL4 antibody sequences, and the 4P14 sequences in the scFv sequences. The sequencing results were translated into protein amino acid sequences as shown in the above SEQ ID NO: 10, SEQ ID NO: 11, and SEQ ID NO: 12.

[0112] Example 2 Preparation of 4P14-IgG1, 4P14-IgG2, 4P14-IgG3, and 4P14-IgG4 antibodies

[0113] First, take the 4P14 sequence screened in Example 1;

[0114] Secondly, the VH sequence of 4P14 sequence was used to replace the VH sequence of IgG1, IgG2, IgG3, and IgG4 antibodies respectively; the VL sequence of 4P14 sequence was used to replace the VL region of the corresponding kappa light chain in IgG1, IgG2, IgG3, and IgG4 antibodies respectively;

[0115] Next, the replaced light chain and heavy chain were constructed into the expression vector pcDNA3.1, respectively, to obtain the expression vectors of 4P14-IgG1, 4P14-IgG2, 4P14-IgG3, and 4P14-IgG4 antibodies;

[0116] Subsequently, each expression vector was transiently transfected into HEK293 cells, and 4P14-IgG1, 4P14-IgG2, 4P14-IgG3, and 4P14-IgG4 expression plasmids were transiently transfected into HEK293 cells and transiently expressed in HEK293 cells; HEK293 cells continued to grow for 3-5 days after transfection, and cells were counted every day; when the cell viability was less than 60%, the culture supernatant was collected by centrifugation;

[0117] Finally, the collected culture supernatant was filtered, and the 4P14-IgG1, 4P14-IgG2, 4P14-IgG3, and 4P14-IgG4 antibodies in the filtrate were purified using AKAT Purifier 100 (GE Healthcare) and Protein A Sepharose 4 Fast Flow column (GE Healthcare).

[0118] The expression vectors of 4P14-IgG1, 4P14-IgG2, 4P14-IgG3, and 4P14-IgG4 antibodies were sequenced, and the sequencing results were translated into protein sequences as follows:

[0119] 2.1) Amino acid sequences of the light and heavy chains of 4P14-IgG1

[0120] The heavy chain sequence of 4P14-IgG1 is shown in SEQ ID NO:13:

[0121] QVQLVQSGGGLVKPGGSLRLSCAASGFTLSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARAGSAGAAGSYYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK;

[0122] The kappa light chain sequence of 4P14-IgG1 is shown in SEQ ID NO:14:

[0123] DIQLTQSPSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGRDFSLTISSLQPEDFATYYCQQSHSSQYTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC;

[0124] 2.2) Amino acid sequences of the light and heavy chains of 4P14-IgG2

[0125] The heavy chain sequence of 4P14-IgG2 is shown in SEQ ID NO:15:

[0126] QVQLVQSGGGLVKPGGSLRLSCAASGFTLSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARAGSAGAAGSYYYYGM DVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSNFGTQTYTCNVDHKPSNTKVDKTVER KCCVECPPCPAPPVAGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTFRVVSVLTVVHQDWLNGKEYKCKVSNKGLPAPIEK TISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPMLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK;

[0127] The kappa light chain sequence of 4P14-IgG2 is shown in SEQ ID NO: 14;

[0128] 2.3) Amino acid sequences of the light and heavy chains of 4P14-IgG3

[0129] The heavy chain sequence of 4P14-IgG3 is shown in SEQ ID NO:16:

[0130] QVQLVQSGGGLVKPGGSLRLSCAASGFTLSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARAGSAGAAGSYYYYGMDVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYTCNVNHKPSNTKVDKRVELKTPLGDTTHTCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPEPKSCDTPPPCPRCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVQFKWYVDGVEVHNAKTKPREEQYNSTFRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKTKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESSGQPENNYNTTPPMLDSDGSFFLYSKLTVDKSRWQQGNIFSCSVMHEALHNRFTQKSLSLSPGK;

[0131] The kappa light chain sequence of 4P14-IgG3 is shown in SEQ ID NO:14;

[0132] 2.4) Amino acid sequences of the light and heavy chains of 4P14-IgG4

[0133] The heavy chain sequence of 4P14-IgG4 is shown in SEQ ID NO:17:

[0134] QVQLVQSGGGLVKPGGSLRLSCAASGFTLSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARAGSAGAAGSYYYYGM DVWGQGTTVTVSSASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSNTKVDKRVESK YGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEK TISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK;

[0135] The kappa light chain sequence of 4P14-IgG4 is shown in SEQ ID NO:14.

[0136] Example 3 Affinity detection of 4P14-IgG1 antibody

[0137] In this example, the candidate antibody prepared in Example 2 was selected for affinity testing.

[0138] Recombinant human and mouse DLL4 proteins were used to coat ELISA plates, and the affinity of candidate antibodies to human and mouse DLL4 was tested by ELISA.

[0139] The detection method is as follows:

[0140] 3.1 Coating: Coat the ELISA plate with 100 μL / well of recombinant human DLL4 and mouse DLL4 antigen proteins at a concentration of 1 ug / ml. Coat each well of the 96-well plate with each antigen protein. After coating, seal the plate with a sealing film and incubate at 4°C for 12 hours.

[0141] 3.2. Blocking: discard the ELISA plate coating solution, add 300 μL of PBST to each well, wash for 1 min, and repeat this step 5 times; add 300 μL / well of PBS (PBSM) containing 5% skim milk powder to block for 1 hour; after blocking, discard the blocking solution, add 300 μL of PBST, wash for 1 min, and repeat this step 5 times;

[0142] 3.3. Incubation with primary antibody: The starting concentration of 4P14-IgG1 antibody is 100 μg / ml. Dilute the antibody three times with PBSM in a 5-fold gradient. Add 100 μL / diluted antibody sample in sequence and incubate at 37°C for 1 hour.

[0143] 3.4. Incubate with secondary antibody: Wash 20 times with PBST; after washing, prepare rabbit anti-human IgG H&L (HRP) (dilution: 1:130000, abcam) in PBSM, add 100 μL / well of secondary antibody, and incubate at 37°C for 1 hour;

[0144] 3.5. Color development: Wash 20 times with 1×PBST, add 100μL TMB, color develop for 10 min in dark, add 50μL stop solution / well to stop color development, detect OD450 on a microplate reader, and record the relevant values;

[0145] 3.6. Analysis: Draw the antibody IC50 curve based on the OD450 readings and draw an affinity graph.

[0146] The affinity curve of 4P14-IgG1 to human and mouse DLL4 detected by ELSIA is shown in the figure Figure 1 As shown; Figure 1 In the figure, hDLL4 represents the affinity curve of 4P14-IgG1 for human; mDLL4 represents the affinity curve of 4P14-IgG1 for mouse.

[0147] Example 4 Specific detection of DLL4 by 4P14-IgG1 antibody

[0148] DLL4 has two homologous family members, DLL1 and DLL3, which have high homology. The screened 4P14 antibody may bind to DLL1 and DLL3. Therefore, it is necessary to detect the binding specificity of 4P14 to DLL4 to exclude the possibility of its binding to DLL1 and DLL4.

[0149] The specific detection methods are as follows:

[0150] 4.1. Take out the pre-cultured DLL4 overexpression cell line 293T-DLL4 (identified as group number 1#), DLL1 overexpression cell line 293T-DLL1 (identified as group number 2#), and 293T-DLL3 overexpression cell line 293-DLL3 cells (identified as group number 3#), wash with DPBS, digest with trypsin, resuspend in medium containing 10% DMEM, and count the cells in the resuspension respectively;

[0151] 4.2. According to the counting results, take the cell suspension from group 1#, 2#, and 3# and plate it into the cell wells of a 96-well plate, and add 100 μL / well. Each cell is plated at 1.0×10 5Each group of 10 wells corresponds to group number 1#, 2#, and 3#.

[0152] 4.3. Dilute the 4P14-IgG1 antibody at a concentration of 100 μg / mL in 10 steps by 3 times;

[0153] 4.4. Centrifuge the 96-well plate at room temperature at 500 g for 5 minutes and discard the supernatant. Add 4P14-IgG1 antibody to the corresponding cell wells of the 96-well plate at 100 μL / well, and then incubate the 96-well plate at room temperature for 20 minutes.

[0154] After 20 minutes of incubation, 150 μL of DPBS (containing 2% FBS) was added to each well for washing, and then the 96-well plate was centrifuged at 500 g for 5 minutes at room temperature; the supernatant was discarded; 250 μL of DPBS (containing 2% FBS) was added to each well for washing, and the 96-well plate was centrifuged at 500 g for 5 minutes at room temperature; the supernatant was discarded;

[0155] 4.5. According to the grouping scheme (identified as group number 1#, 2#, 3#), add 100 μL of secondary antibody diluent to each well and incubate at room temperature for 20 minutes; the secondary antibody diluent is anti-human IgG Fc Antibody PE and the concentration is 0.5 μL / well;

[0156] 5.6. After 20 min incubation, add 150 μL DPBS (containing 2% FBS) to each well for washing twice, centrifuge the 96-well plate at 500 g for 5 min at room temperature, and discard the supernatant;

[0157] 4.7. Add 120 μL DPBS (containing 2% FBS) to each well of the 96-well plate for resuspending, and the resuspended liquid in each well is tested independently on the flow cytometer.

[0158] 4.8. The specific detection results of 4P14 by flow cytometry for 293T-DLL4 cells, 293T-DLL1 cells and 293T-DLL3 cells are as follows Figure 2 shown.

[0159] Figure 2 The results show that 4P14-IgG1 can detect the expression of DLL4 in 293T-DLL4 cells with high affinity, while 4P14-IgG1 hardly binds to 293T-DLL1 and 293T-DLL3, respectively, and has no affinity. In other words, 4P14 only binds to DLL4, not to DLL1 and DLL3, and has high specificity. Therefore, 4P14-IgG1 can be used as a specific detection reagent for flow cytometry to detect the expression of DLL4 on cells.

[0160] Example 5 Construction of CD3×DLL4 BiTE

[0161] 5.1 Design of CD3×DLL4 BiTE

[0162] The sequence of the anti-CD3E antibody of blinatumomab and the sequence of the 4P14 antibody were used to construct BiTE, and the schematic diagram of its structure is shown in the figure. Figure 3 shown.

[0163] 5.1.1. Connect the VH and VL of 4P14 with (G4S)3 to construct 4P14 scFv;

[0164] 5.1.2. The anti-CD3E scFv of blinatumomab and 4P14 scFv were connected through G4S, the signal peptide SP was added to the N-terminus of the anti-CD3E scFv, and the 6×His tag was added to the C-terminus of 4P14. The SP-anti-CD3E scFv-G4S-4P14 scFv-6×His gene fragment was fully synthesized and returned to the PUC57 plasmid vector to construct CD3×DLL4 BiTE.

[0165] The amino acid sequence of CD3×DLL4 BiTE is shown in SEQ ID NO: 18:

[0166] .

[0167] 5.2 Construction of pcDNA3.1-CD3×DLL4 eukaryotic expression vector

[0168] 5.2.1, double-digest SP-anti-CD3EscFv-G4S-4P14scFv-6×His and pcDNA3.1 with Hind III (commercially purchased from NEB) and EcoR I (commercially purchased from NEB) to obtain their respective broken chain genes;

[0169] 5.2.2. The broken strand genes were purified and mixed, T4 ligase (commercially available from NEB) was added, and the reaction was carried out at 16°C for 12 hours to obtain the ligation product;

[0170] 5.2.3. Spread the ligation product on an LB plate containing ampicillin to obtain colonies;

[0171] 5.2.4. Pick a single colony grown on the plate, transfer it to 3 ml of liquid LB medium, place it in a 13 ml bacterial culture tube, and culture it at 37°C, 220 rpm, shaking for 12 hours to obtain a bacterial solution;

[0172] 5.2.5. Take a sample of the bacterial solution and send it for sequencing. If the measured sequence is consistent with the constructed sequence SEQ ID NO: 18, it means that the pcDNA3.1-CD3×DLL4 eukaryotic expression vector is successfully constructed.

[0173] 5.3 Transfection of CHO cells

[0174] Extract the transfection-grade plasmid of pcDNA3.1-CD3×DLL4 and use X-tremeGENE TM 9DNA Transfection Reagent (commercially available from Roche) was used to transfect CHO cells. The plasmid and transfection agent PEI were mixed at a ratio of 1:3, and added dropwise to 50 ml of CHO-S cells. The cells were cultured on a shaker at 37°C, 5% CO2, and 150 rpm for 7 days to obtain the supernatant containing CD3×DLL4 BiTE protein.

[0175] 5.4 Purification and concentration determination of CD3×DLL4 BiTE protein

[0176] 5.4.1. Collect the supernatant on the 7th day after transfection, centrifuge at 8000 rpm for 20 min, and collect the supernatant again;

[0177] 5.4.2. The CD3×DLL4 BiTE protein in the supernatant was purified using Akat Prime Plus protein purifier and HisTrap HP (commercially available from GE);

[0178] 5.4.3. The purified protein was concentrated to 1 ml using a 30KDa ultrafiltration tube at 3000 rpm for 30 min.

[0179] 5.5.4. The molecular size and purity of the purified CD3×DLL4 BiTE protein were detected by SDS-PAGE. Figure 4 shown.

[0180] Figure 4 In the SDS-PAGE denaturing gel image, a clear band was shown at 54 kDa with a purity of >90%, indicating that the CD3×DLL4 BiTE protein was obtained and expressed successfully.

[0181] Example 6 Identification of biological functions of CD3×DLL4 BiTE protein

[0182] To verify whether both CD3 and DLL4 sites of CD3×DLL4 BiTE protein have binding activity, flow cytometry was used to detect whether DLL4-overexpressing cell line 293T-DLL4 and T cells bind to CD3×DLL4BiTE.

[0183] 6.1 Identification of the bifunctionality of CD3×DLL4 BiTE

[0184] 6.1.1, respectively, 5×10 5 293T-DLL3 cells and T cells were incubated with 10 μg / mL CD3×DLL4 BiTE on ice for 60 min;

[0185] 6.1.2. After the incubation, the two types of cells were washed once with PBS containing 0.5% bovine serum albumin (PBSA), and each was resuspended with 100 μl PBSA;

[0186] 6.1.3. Add 1 μL of secondary antibody Anti-G4S linker (B02H1) mAb (PE) (Shanghai Heyousheng Biotechnology Co., Ltd.) to the resuspension and incubate for 30 min. In the negative control group, only the secondary antibody was added.

[0187] 6.1.4. After the incubation, both cells were washed once with PBSA and then used for flow cytometry analysis. The results of flow cytometry analysis were as follows: Figure 5 As shown; wherein, label 1 represents 293T-DLL4 cells without the addition of CD3×DLL4 BiTE, label 2 represents 293T-DLL4 cells with the addition of CD3×DLL4 BiTE, label 3 represents T cells without the addition of CD3×DLL4 BiTE, and label 4 represents T cells with the addition of CD3×DLL4 BiTE.

[0188] Figure 5 The display showed that after adding CD3×DLL4 BiTE, both 293T-DLL4 and T cells showed peak shift, indicating that CD3×DLL4 BiTE can bind well to 293T-DLL4 and T cells.

[0189] 6.2 Ability of CD3×DLL4 BiTE to activate T cells

[0190] 6.2.1. One day before the T cell activation experiment, dilute the target cells 293T-DLL4 cells and the control cells 293T to 4×10 5 Cell suspension of 100 cells / ml was inoculated into 96-well plates at 100 μL per well and incubated for 16 h;

[0191] 6.2.2. After the incubation, aspirate all the supernatant from each well, and then immediately add 25 μl of DMEM complete medium; perform a 3-fold gradient dilution of CD3×DLL4 BiTE at a concentration of 100 μg / mL, dilute 9 gradients, and add the dilutions to the corresponding wells of 293T-DLL4 target cells and control cells 293T in the prepared 96-well plate. Each gradient dilution is added to 3 wells, and the third well is a blank control well. Add 25 μL to each well;

[0192] 6.2.3, according to 2×10 5 Add 25 μl of effector cells Jurkat-NFAT-CD3 to the corresponding wells of 293T-DLL4 target cells and control cells 293T, respectively; the final volume of each well is 75 μl;

[0193] 6.2.4. Cover the plate with the cover and place the plate in a 37°C, 5% CO2 humidified incubator for 6 hours;

[0194] 6.2.5. After incubation, remove the 96-well plate, let it stand at room temperature, and add 75 μl of BioGlo to each well of the 293T-DLL4 target cells and control cells. TM Luciferase detection reagent; incubate at room temperature in the dark for 10 min, then place Discovery System (Promega) was used to detect the luminescence value. The results were as follows Figure 6 shown.

[0195] Figure 6 It was shown that 293T-DLL4 cells co-incubated with CD3×DLL4 BiTE could activate effector cells Jurkat-NFAT-CD3, while 293T cells co-incubated with CD3×DLL4 BiTE could not activate effector cells Jurkat-NFAT-CD3; this indicates that 293T-DLL4 cells can specifically activate T cells through CD3×DLL4 BiTE.

[0196] 6.3CD3×DLL4 BiTE mediates T cell killing of 293T-DLL4 cells

[0197] 6.3.1. 293T-DLL4 cells and 293T cells were used as target cells to detect whether CD3×DLL4 BiTE could mediate T cell targeting and specific killing of 293T-DLL4 cells expressing DLL4.

[0198] 6.3.2. Take target cells 293T-DLL4 and control cells 293T and add 1×10 4Cells / well were plated on E-plate-16 plates, 100 μL was added to each well, and the growth of target cells was observed. When the proliferation curve exceeded 0.6, 25 μL of supernatant was aspirated;

[0199] 6.3.3. CD3×DLL4 BiTE at a concentration of 10 μg / ml was diluted five-fold to obtain a total of 5 gradient dilutions. Each gradient dilution was added to the wells of the coated 293T-DLL4 target cells and the control cells 293T, with 25 μL added to each well. T cells were added at a ratio of 3:1 according to the number of wells plated with target cells, with a volume of 50 μl added to each well.

[0200] 6.3.4. Place the E-plate-16 plate into the xCELLigence RTCA DP and collect and analyze data after the killing effect is stable; the analysis results are as follows: Figure 7 shown.

[0201] Figure 7 The results showed that different doses of CD3×DLL4 BiTE mediated T cell killing of 293T-DLL4 cells. The higher the dose, the higher the killing rate. However, the highest dose of CD3×DLL4 BiTE had only a weak killing effect on 293T cells, and even CD3×DLL4 BiTE could not mediate T cell killing of 293T cells. Therefore, CD3×DLL4 BiTE mediated T cells to have a dose-dependent targeted killing effect on cells expressing DLL4.

[0202] Example 7 4P14 CAR lentiviral packaging and related functional verification after T cell infection

[0203] 7.1 Construction of 4P14 CAR Lentiviral Plasmid

[0204] 7.1.1、4P14 CAR structure diagram is as follows Figure 8 As shown in the figure, the signal peptide CD8αSP, antigen recognition domain 4P14scFv, hinge region CD8αHinger, transmembrane domain CD8αTM, costimulatory domain 4-1BB and CD3Zeta sequences are connected from N-terminus to C-terminus to construct 4P14 CAR.

[0205] 7.1.2. Through PCR reaction, restriction sites EcoRI and BamHI were introduced at both ends of the 4P14 CAR sequence, and after double digestion with EcoRI and BamHI, cloned into the lentiviral vector to construct the lentiviral plasmid p4P14.

[0206] The amino acid sequence of 4P14 CAR is shown in SEQ ID NO: 19:

[0207] MALPVTALLLPLALLLHAARPQVQLVQSGGGLVKPGGSLRLSCAASGFTLSDYYMSWIRQAPGKGLEWVSYISSSGSTIYYADSVKGRFTISRDNAKNSLYLQMNSLRAEDTAVYYCARAGSA GAAGSYYYYGMDVWGQGTTVTVSSGGGGSGGGGSGGGGSDIQLTQSPSSSLSASVGDRVTITCQASQDISNYLNWYQQKPGKAPKLLIYDASNLETGVPSRFSGSGSGRDFSLTISSLQPEDFA TYYCQQSHSSQYTFGQGTKVEIKTTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACDIYIWAPLAGTCGVLLLSLVITLYKRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRF PEEEEGGCELRVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR.

[0208] In the CAR structure, the signal peptide, hinge region, transmembrane region, intracellular co-stimulatory domain and other sequences translated into proteins are combined preferentially; the protein amino acid sequences translated into proteins are as follows:

[0209] 1) The amino acid sequence of the signal peptide SP is any of the following:

[0210] The amino acid sequence of IL-2SP is shown in SEQ ID NO: 20: MYRMQLLSCIALSLALVTNS;

[0211] The amino acid sequence of IL-21SP is shown in SEQ ID NO: 21: MRSSPGNMERIVICLMVIFLGTLV;

[0212] The amino acid sequence of CD8αSP is shown in SEQ ID NO: 22: MALPVTALLLPLALLLHAARP;

[0213] The amino acid sequence of CSF2SP is shown in SEQ ID NO: 23: MWLQSLLLLGTVACSIS;

[0214] The amino acid sequence of DAP12SP is shown in SEQ ID NO: 24: MGGLEPCSRLLLLPLLLAVSG;

[0215] The amino acid sequence of CD16SP is shown in SEQ ID NO: 25: MWQLLLPTALLLLVSA;

[0216] The amino acid sequence of CD56SP is shown in SEQ ID NO: 26: MLQTKDLIWTLFFLGTAVS;

[0217] The amino acid sequence of IL-8SP is shown in SEQ ID NO: 27: MTSKLAVALLAAFLISAALC;

[0218] 2) The amino acid sequence of the hinge region is any of the following:

[0219] The amino acid sequence of the hinge region of CD8α is shown in SEQ ID NO:28:

[0220] TTTPAPRPPTPAPTIASQPLSLRPEACRPAAGGAVHTRGLDFACD;

[0221] The amino acid sequence of the hinge region of CD28 is shown in SEQ ID NO: 29:

[0222] IEVMYPPPYLDNERSNGTIIHVKGKHLCPSPLFPGPSKP;

[0223] The amino acid sequence of the hinge region of IgG1 is shown in SEQ ID NO:30: AEPKSPDKTHTCPPCPKDPK;

[0224] The amino acid sequence of the hinge region of IgG4 is shown in SEQ ID NO:31: ESKYGPPCPPCP;

[0225] 3) The amino acid sequence of the transmembrane region is any of the following:

[0226] The amino acid sequence of the CD8α transmembrane region is shown in SEQ ID NO:32: IYIWAPLAGTCGVLLLSLVITLY;

[0227] The amino acid sequence of the CD4 transmembrane region is shown in SEQ ID NO:33: MALIVLGGVAGLLLFIGLGIFF;

[0228] The amino acid sequence of the CD28 transmembrane region is shown in SEQ ID NO:34:

[0229] FWVLVVVGGVLACYSLLVTVAFIIFWV;

[0230] The amino acid sequence of the CD3ζ transmembrane region is shown in SEQ ID NO:35: LCYLLDGILFIYGVILTALFL;

[0231] 4) The amino acid sequence of the intracellular co-stimulatory domain is any of the following:

[0232] The amino acid sequence of CD3ζ is shown in SEQ ID NO:36:

[0233] RVKFSRSADAPAYKQGQNQLYNELNLGRREEYDVLDKRRGRDPEMGGKPRRKNPQEGLYNELQKDKMAEAYSEIGMKGERRRGKGHDGLYQGLSTATKDTYDALHMQALPPR;

[0234] The amino acid sequence of 4-1BB is shown in SEQ ID NO: 37, or any of the following:

[0235] KRGRKKLLYIFKQPFMRPVQTTQEEDGCSCRFPEEEEGGCEL;

[0236] The amino acid sequence of ICOS is shown in SEQ ID NO:38:

[0237] CWLTKKKYSSSVHDPNGEYMFMRAVNTAKKSRLTDVTL;

[0238] The amino acid sequence of OX40 is shown in SEQ ID NO:39:

[0239] ALYLLRRDQRLPPDAHKPPGGGSFRTPIQEEQADAHSTLAKI;

[0240] The amino acid sequence of CD27 is shown in SEQ ID NO:40:

[0241] QRRKYRSNKGESPVEPAEPCHYSCPREEEGSTIPIQEDYRKPEPACSP;

[0242] The amino acid sequence of CD28 is shown in SEQ ID NO:41:

[0243] RSKRSRLLHSDYMNMTPRRPGPTRKHYQPYAPPRDFAAYRS.

[0244] 7.2 Packaging of 4P14 CAR Lentivirus

[0245] 7.2.1. Take out the cultured 293T cell culture flask from the CO2 incubator and 6 Inoculate the cells into the wells of a T75 cell culture plate, add DMEM complete medium to each well to 15 mL; move the culture flask in a "M" shape to evenly spread the 293T cells in the culture dish;

[0246] 7.2.2. Transfer the culture plate to a CO2 incubator for culture. After 18 to 24 hours, remove the 293T cells plated the day before from the CO2 incubator, discard the old culture medium, replace with 7.5 mL of serum-free DMEM medium, and return to the CO2 incubator for further culture for 1 hour.

[0247] 7.2.3. During the cell culture process, prepare the reagents required for transfection: take two 15 mL centrifuge tubes, mark them as A and B respectively; add 940 μL OPti-MEM and 80 μL PEI to tube A, add 940 μL OPti-MEM and 40 μg total plasmid to tube B, where the amount of each plasmid follows the mass ratio of gag / pol:Rev:VSV-G:p4P14=2:2:1:3. When the transfection time is approaching, add the mixed solution in tube A to tube B, and let it stand at room temperature for 20 minutes to obtain the transfection mixture;

[0248] 7.2.4 After 1 hour of cell culture, add the transfection mixture to the cells in each well of the culture plate and mix well. Transfer the culture plate to the incubator for transfection again.

[0249] 7.2.5. 6 hours after transfection, remove the 293T cells, discard the old culture medium, and replace it with 15 mL of DMEM complete culture medium. After continuing transfection for 30 hours, carefully remove the 293T cells and collect the lentiviral supernatant in a 50 mL centrifuge tube;

[0250] 7.2.6. Transfer the collected lentiviral supernatant to ultrafiltration tubes respectively, centrifuge at 4°C and 3800 rpm for 30 min; remove the ultrafiltration tubes, discard the filtrate, continue centrifugation for 10 min, and remove the supernatant; collect the concentrated and purified lentivirus, and dispense into 1.5 mL Eppendorf tubes, 100 μL per tube, for later use.

[0251] 7.3 Lentiviral titer determination

[0252] 7.3.1. Take the cultured Jurkat cells, centrifuge at 400g for 4 min, resuspend in serum-free 1640 medium, and count; 6 cells / well, add the cell suspension to each well of the culture plate, add 250uL of cell suspension to each well;

[0253] 7.3.2. Add the purified lentivirus to the wells of the culture plate in the order of 5 μL, 1 μL, 0.2 μL, and 0.04 μL of lentivirus gradient; after continuing to culture for 18-24 hours, collect the cells and perform flow cytometry detection; according to the CAR positive rate test results of Jurkat cells, the lentivirus titer was calculated to be 6.07×10 7 TU / ml.

[0254] 7.4 Preparation of 4P14 CAR-T cells

[0255] 7.4.1 Use FlowComp TM Human CD3 (commercially purchased from ThermoFisher), to sort T cells from PBMCs and count the sorted T cells;

[0256] 7.4.2. Take the sorted T cells and culture them in a 37°C, 5% CO2 incubator for 24 hours;

[0257] 7.4.3. After the culture is completed, add lentivirus to each well of the culture plate at a ratio of MOI = 3, mix well, return to the incubator for transfection culture, and replenish the culture medium every two days;

[0258] 7.4.4. After transfection and culture for 13 days, the expression of CAR on the surface of T cells was detected by flow cytometry; the test results were as follows: Fig. 9 Shown

[0259] Fig. 9 The results showed that the CAR positivity rate of 4P14 CAR-T cells was 98.9%, indicating that 4P14 CAR-T cells were successfully prepared.

[0260] Example 8 Verification of the in vitro killing rate of 4P14 CAR-T on target cells 293T-DLL4

[0261] 293T-DLL4 cells and 293T cells were used as target cells to detect whether 4P14 CAR-T cells could target and specifically kill 293T-DLL4 cells expressing DLL4.

[0262] The test process is as follows:

[0263] 8.1. Take target cells 293T-DLL4 and control cells 293T and add 1×10 4 Cells / well were plated into the wells of E-plate-16, 100 μL was added to each well, and the growth of target cells was observed. When the proliferation curve exceeded 0.6, E-Plate 16 was taken out and placed in a clean bench;

[0264] 8.2. According to the number of target cells plated, add 4P14 CAR-T and T cells at a ratio of 3:1, with a volume of 50 μl per well;

[0265] 8.3. Place the E-plate-16 plate into the xCELLigence RTCA DP and collect and analyze data after the killing effect is stable; the results are as follows Fig.10 shown.

[0266] Fig.10 The results showed that under experimental conditions, 4P14 CAR-T cells had a significant specific killing effect on target cells 293T-DLL4, while the killing ability on control cells 293T was equivalent to the nonspecific killing of T cells. T cells had nonspecific killing of 293T-DLL4 cells, and the killing ability was much lower than that of 4P14 CAR-T cells; that is, compared with the T cell group, 4P14CAR-T cells had a significant killing activity on 293T-DLL4, while the killing activity on 293T was equivalent, indicating that 4P14 CAR-T cells had a specific killing effect on cells expressing DLL4.

[0267] Example 9: Verification of the in vivo killing rate of 4P14 CAR-T on Lewis lung cancer cells

[0268] Lewis lung cancer cells were subcutaneously inoculated into 20 6-8 week old NSG male mice (weight 18-22 g), with each mouse inoculated with 5×10 6 The injection sites of the mice were observed every day, and the tumor volumes of the mice were measured using a vernier caliper.

[0269] The test process is as follows:

[0270] 9.1. When the tumor volume reaches 100 mm 3 , According to the weight and tumor size of mice, they were randomly divided into 3 groups (i.e., blank control group, T cell group, and 4P14 CAR-T cell group), with 5 mice in each group;

[0271] 9.2. Intravenous injection of mice in each cell group:

[0272] In the 4P14 CAR-T cell group, 5×10 6 4P14 CAR-T cells / 200 μl;

[0273] T cell group, 5×10 6 T cells / 200 μl;

[0274] In the blank control group, 200 μl of DPBS was injected into the tail vein of mice;

[0275] 9.3. After the mice were treated by tail vein injection, the tumor volume of the mice was measured with a vernier caliper every other day. The observation ended after 28 days, and the number of surviving mice was recorded every day until the end of the 28th day.

[0276] The curve of mouse tumor volume change is shown in Fig.11 The mouse survival rate curve is shown in Fig.12 shown. Fig.11 The results showed that 4P14 CAR-T can significantly reduce tumor volume, while T cells and DPBS cannot reduce tumor volume; these indicate that the tumor volume of mice treated with 4P14CAR-T was significantly reduced, and 4P14 CRA-T had a significant tumor inhibitory effect; while the tumor volume of mice in the T cell and DPBS control group continued to increase, and there was no tumor inhibitory effect.

[0277] Fig.12 The results showed that after 4P14 CAR-T treatment, only one mouse died within 28 days, while 4 mice died in the DPBS group and 3 mice died in the T cell group. Therefore, compared with T cell DPBS, 4P14 CAR-T can prolong the survival of mice and has a significant tumor inhibition effect; that is, the survival rate of mice treated with 4P14 CAR-T is higher, showing a better therapeutic effect.

[0278] It should be understood that the above description of the preferred embodiments of the present invention is relatively detailed and cannot be regarded as limiting the scope of patent protection of the present invention. The scope of patent protection of the present invention shall be based on the attached claims.

Claims

1. A DLL4 antibody, characterized in that The scFv sequence of the DLL4 antibody contains a 4P14 sequence.

2. The DLL4 antibody according to claim 1, characterized in that The amino acid sequence of the heavy chain variable region of the scFv sequence is shown in SEQ ID NO:11, and the amino acid sequence of the light chain variable region of the scFv sequence is shown in SEQ ID NO:

12.

3. The DLL4 antibody according to claim 2, characterized in that The amino acid sequences of the three heavy chain complementary determining regions HCDR1, HCDR2, and HCDR3 in the 4P14 sequence and the amino acid sequences of the three light chain complementary determining regions LCDR1, LCDR2, and LCDR3 in the 4P14 sequence are as follows: When the 4P14 sequence is a chothia structure, in the 4P14 sequence: the amino acid sequence of HCDR1 is GFTLSDY, the amino acid sequence of HCDR2 is SSSGST, the amino acid sequence of HCDR3 is AGSAGAAGSYYYYGMDV, the amino acid sequence of LCDR1 is QASQDISNYLN, the amino acid sequence of LCDR2 is DASNLET, and the amino acid sequence of LCDR3 is QQSHSSQYT; or When the 4P14 sequence is a Kabat structure, in the 4P14 sequence: the amino acid sequence of HCDR1 is DYYMS, the amino acid sequence of HCDR2 is YISSSGSTIYYADSVKG, the amino acid sequence of HCDR3 is AGSAGAAGSYYYYGMDV, the amino acid sequence of LCDR1 is QASQDISNYLN, the amino acid sequence of LCDR2 is DASNLET, and the amino acid sequence of LCDR1 is QQSHSSQYT.

4. An IgG antibody, characterized in that The IgG antibody comprises the amino acid sequence of the heavy chain variable region and the amino acid sequence of the light chain variable region of the DLL4 antibody according to any one of claims 1 to 3.

5. A bispecific T cell engager, characterized in that The structure of the linker comprises the amino acid sequence of the heavy chain variable region and the amino acid sequence of the light chain variable region of the DLL4 antibody according to any one of claims 1 to 3.

6. A CAR structure, characterized in that: The CAR structure comprises the amino acid sequence of the heavy chain variable region and the amino acid sequence of the light chain variable region of the DLL4 antibody according to any one of claims 1 to 3.

7. A detection reagent, characterized in that: The detection reagent comprises the DLL4 antibody according to any one of claims 1 to 3, or the IgG antibody according to claim 4, or the bispecific T cell engager according to claim 5, or the CAR structure according to claim 6.

8. Use of the detection reagent according to claim 7 in detecting tumor cells or cancer cells.

9. A biological agent, characterized in that: The biological preparation comprises the DLL4 antibody according to any one of claims 1 to 3, or the IgG antibody according to claim 4, or the bispecific T cell engager according to claim 5, or the CAR structure according to claim 6.

10. Use of the biological preparation according to claim 9 in the preparation of drugs for treating tumors and cancers.